Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | PPP1R15A | O75807 | 1/20 | 0.55 |
| ▸ | MELK | Q14680 | 1/20 | 0.55 |
| ▸ | PPP1R15B | Q5SWA1 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256569 | 0.82 | GRIN2D (0.52) | NPSR1SMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL1614520 | 0.79 | PPP1R15A (0.36) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL6847216 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL30275282 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL32680261 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL534017 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL534016 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL2161103 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL13128176 | 0.78 | L3MBTL1 (0.50) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL14480083 | 0.78 | L3MBTL1 (0.50) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488491-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-8017607-B2 | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017607-B2 | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017607-B2 | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2011045257-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | BARTKOVITZ DAVID JOSEPH | 2011-04-14 | — | — | US | disclosed |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | BARTKOVITZ DAVID JOSEPH | 2011-04-14 | — | — | US | disclosed |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | BARTKOVITZ DAVID JOSEPH | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | MDM2, TP53, TP53BP1 | L3MBTL1 2865/4885PPP1R15A 285/4885MELK 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.